Press coverage about Cerecor (NASDAQ:CERC) has trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cerecor earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.4384620248378 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Cerecor (CERC) traded down $0.05 during midday trading on Tuesday, hitting $1.10. The stock had a trading volume of 175,727 shares, compared to its average volume of 475,264. Cerecor has a 52 week low of $0.34 and a 52 week high of $5.60.

Cerecor (NASDAQ:CERC) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.14) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.15. Cerecor had a negative return on equity of 1,325.84% and a negative net margin of 1,106.99%. The company had revenue of $0.16 million during the quarter. research analysts forecast that Cerecor will post -0.8 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at

In other Cerecor news, major shareholder Armistice Capital Master Fund acquired 219,792 shares of the business’s stock in a transaction dated Monday, August 21st. The stock was bought at an average price of $0.60 per share, with a total value of $131,875.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have bought 1,638,693 shares of company stock valued at $1,053,475 in the last three months. 10.70% of the stock is owned by insiders.

About Cerecor

Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Stock Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related stocks with our FREE daily email newsletter.